[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609037":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":54,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ropivacaine group","ACTIVE_COMPARATOR","0.5% ropivacaine was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder at about 30 min before surgical incision",[13],"Drug: Ropivacaine",{"label":15,"type":16,"description":17,"interventionNames":18},"FA+Ropivacaine group","EXPERIMENTAL","5mg FA and 0.5% ropivacaine was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder at about 30 min before surgical incision",[19],"Drug: FA+Ropivacaine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","FA+Ropivacaine","0.5 mL FA (50 mg; 5 mL; by Beijing Taide Pharmaceutical Co., Ltd) and 15 mL of 1% ropivacaine (Nai Le Pin 10mg\u002FmL; by AstraZeneca AB, Sweden) diluted to a total volume of 30 mL in normal saline",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Ropivacaine","15 mL of 1% ropivacaine diluted to a total volume of 30 mL in normal saline",[9],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Fang Luo, MD","CONTACT","+86 5997 6660","13611326978@163.com",{"name":38,"role":34,"phone":35,"phoneExt":26,"email":39},"Wei Zhang, MD","13810045210@163.com",[41],{"facility":5,"status":42,"city":43,"state":26,"zip":26,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Beijing","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Fang Luo","Professor","100609037","pre-emptive-scalp-infiltration-with-low-dose-flurbiprofen-and-ropivacaine-for-postoperative-analgesia-after-craniotomy-100609037",false,"NCT07209345","Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy","Inclusion Criteria:\n\n1. Age 18-64 years;\n2. ASA physical status of I - II;\n3. Scheduled for craniotomy under general anesthesia;\n4. Anticipated tracheal extubation, recovery of consciousness and orientation within 2 hours after craniotomy.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale \\\u003C15;\n2. Unable to use the PCIA device or comprehend the pain NRS;\n3. History of opioid dependence, chronic headache or intake of any drugs with known analgesic properties within the 24 hours before surgery;\n4. Any contraindication to flurbiprofen axetil, such as gastrointestinal ulcer, coagulation disorders, renal dysfunction, heart failure and ischemic heart disease;\n5. History of allergy to any drug used in the study.","ALL","18 Years","64 Years",{"count":68,"type":69},216,"ESTIMATED","INTERVENTIONAL",[72],"NA","Post-craniotomy pain is common and often associated with poor outcomes. Flurbiprofen axetil (FA) is an injectable NSAID for postoperative analgesia, however, the impact of local FA, remains elusive on post-craniotomy pain. As FA is highly lipophilic by merging into emulsified lipid microspheres, it has a high affinity to the surgical incision and inflammatory tissues to achieve targeted drug therapy and prolonged duration of action. On base of the previous report that local NSAIDs achieved therapeutic tissue concentrations despite a plasma concentration of \\\u003C5% of that of systemic administration, a low-dose of FA might be considered a preferential option for local infiltration to avoid anti-platelet related side effects, such as intra-cerebral bleeding. In this study, the investigators attempt to evaluate the clinical effects of pre-emptive scalp infiltration with low-dose FA and ropivacaine for postoperative analgesia after craniotomy.",[75,76],"Post-craniotomy","Pain","2025-11-14",{"date":79,"type":80},"2025-11-17","ACTUAL",{"date":82,"type":80},"2025-10-15",{"date":84,"type":69},"2026-10-15",{"name":5,"class":6},1]